Xiangya Pharmaceutical

Hunan Xiangya Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company established in 1993 and headquartered in Changsha, Hunan. It operates as a key subsidiary of Hunan Fangsheng Pharmaceutical Co., Ltd., which acquired a controlling 53.29% stake in 2010. The company specializes in the research, development, manufacturing, and commercialization of traditional Chinese medicines, modern pharmaceuticals, and health products. Its core commercial portfolio includes cardiovascular and gastrointestinal treatments such as Xuesaitong, Yimaikang, and Jianwei Yuyang capsules, alongside modern drugs like metformin hydrochloride. Additionally, the company is expanding its pipeline with innovative traditional Chinese medicine candidates, such as Sanhua Qingjie granules, which recently received clinical trial approval for acute upper respiratory tract infections.